Premium
Mycophenolate Mofetil and Mood Changes in Children with Skin Disorders
Author(s) -
Arkin Lisa,
Talasila Sreya,
Paller Amy S.
Publication year - 2016
Publication title -
pediatric dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.542
H-Index - 73
eISSN - 1525-1470
pISSN - 0736-8046
DOI - 10.1111/pde.12845
Subject(s) - discontinuation , medicine , mycophenolate , mood , drug , pediatrics , mood disorders , food and drug administration , psychiatry , pharmacology , anxiety , transplantation
The Risk Evaluation and Mitigation Strategy program that the U.S. Food and Drug Administration has mandated has intensified the counseling associated with prescribing mycophenolate mofetil ( MMF ), because of its teratogenicity. In this brief report, two children are described who were prescribed MMF and within weeks developed psychiatric symptoms, with rapid resolution after discontinuation of the medication and no recurrence over 4 years of follow‐up. Mood disorders are a rare but possible side effect that should be mentioned when discussing MMF with patients and families. Prompt discontinuation of the drug should lead to reversal of symptoms when the drug is implicated.